All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Nitric Oxide
Therapeutic Area: Ophthalmology Product Name: NCX 470
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2021
Details:
Nicox’s lead clinical product candidate, NCX 470, is a novel nitric oxide (NO)-donating prostaglandin analog licensed exclusively to Ocumension Therapeutics for the Chinese, Korean and South East Asian markets.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NCX 470
Therapeutic Area: Ophthalmology Product Name: NCX 470
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: HBM Healthcare Investments
Deal Size: $18.1 million Upfront Cash: Undisclosed
Deal Type: Financing December 04, 2020
Details:
The Company was previously financed to complete both the Mont Blanc Phase 3 trial for NCX 470 and the Mississippi Phase 2b trial for NCX 4251. Proceeds from this financing extend the cash runway well beyond these key inflection points.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NCX 470
Therapeutic Area: Ophthalmology Product Name: OT-301
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: OcuMension Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2020
Details:
Denali is a 3-month Phase 3 trial evaluating the safety and efficacy of NCX 470 ophthalmic solution, 0.1%, versus the current standard of care, latanoprost ophthalmic solution, 0.005%, for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lenadogene nolparvovec
Therapeutic Area: Ophthalmology Product Name: Lumevoq
Highest Development Status: Phase III Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2020
Details:
Diamond Pharma Services has provided EU regulatory, pharmacovigilance, quality and compliance support to GenSight, leading to the Marketing Authorisation Application for LUMEVOQ.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lenadogene nolparvovec
Therapeutic Area: Ophthalmology Product Name: Lumevoq
Highest Development Status: Phase III Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2020
Details:
GenSight submitted the MAA based on the benefit-risk balance established by results from a Phase-I/IIa study, two pivotal Phase-III efficacy studies and the long-term follow up study of RESCUE and REVERSET to demonstrate the efficacy of LUMEVOQ®.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NCX 470
Therapeutic Area: Ophthalmology Product Name: NCX 470
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2020
Details:
Nicox completed enrollment of adaptive design patient cohort in its multicenter Mont Blanc Phase 3 trial, evaluating NCX 470 ophthalmic solution vs. latanoprost ophthalmic solution, 0.005% for the lowering intraocular pressure in open-angle glaucoma or ocular hypertension.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lenadogene nolparvovec
Therapeutic Area: Ophthalmology Product Name: Lumevoq
Highest Development Status: Phase III Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2020
Details:
Statistical analysis of the visual acuity in 23 REALITY subjects aged 15 or older with a mutated ND4 gene shows that on average, vision failed to recover from an initial sudden decline, even several years after vision loss.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NCX 470
Therapeutic Area: Ophthalmology Product Name: NCX 470
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2020
Details:
Over 40 sites have been initiated in the first month of the Phase 3 Mont Blanc trial, evaluating NCX 470 for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NCX 470
Therapeutic Area: Ophthalmology Product Name: NCX 470
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: GHO Capital
Deal Size: $5.7 million Upfront Cash: Undisclosed
Deal Type: Divestment July 10, 2020
Details:
The divestment will support Nicox's strategy for rapid advancement of their R&D pipeline and NDA submissions for their two lead product candidates, NCX 470 and NCX 4251.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
